Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Warner Greene from the Gladstone Institute of Virology and Immunology has been trying to solve the mystery of HIV inffection for years, and he thinks he has finally cracked it. In two papers, published simultaneously in Science and Nature, his team lays out why HIV kills so many bystander cells and, better still, a possible way of stopping it.
Scientists say they have discovered a key process by which the AIDS virus kills key immune cells: It triggers a preprogrammed self-destruct sequence within the cell that is intended to alert fellow immune cells of a crisis.
An anti-inflammatory drug shelved by Vertex Pharmaceuticals Inc. after a mid-stage study in epilepsy patients could be the next big HIV treatment.
Should people in danger of contracting HIV because they have risky sex take a pill to prevent infection, or will the medication encourage them to take even more sexual risks? After years of debate on this question, a new international study suggests the medication doesn't lead people to stop using condoms or have more sex with more people.
Taking a pill as a preventive measure against HIV infection may not encourage people at high risk for the disease to engage in risky sexual behavior, according to a new U.S. study meant to address fears about its use.
In July 2012, the Food and Drug Administration (FDA) approved Truvada, the first and only drug intended to prevent HIV infection. Now, a new study provides more proof that regular use of Truvada (emtricitabine and tenofovir disoproxil fumarate) can reduce an individual’s risk of contracting HIV by more than 90 percent. Importantly, the researchers also found that use of the pill does not equate to an increase in risky sexual behavior.
The HIV prevention drug Truvada does not increase risky sexual behaviour, scientists have confirmed.
Health research backer Wellcome Trust awarded Dr. Robert Mahley of the Gladstone Institutes its Seeding Drug Discovery Award on Monday. The $2.5 million grant gives Mahley’s team three years to develop its novel approach to treating Alzheimer’s disease.
Researchers at Gladstone Institutes in San Francisco have created a molecular sensor that can detect multiple sclerosis (MS) early. The method is so precise that MS can be tracked long before disease onset when a patient first presents with symptoms.
A $2.5 million grant to Gladstone Institutes senior investigator and founder Robert Mahley could help lay a new course toward an Alzheimer's disease treatment.